MWNA
RPRX icon

Marshall Wace North America’s Royalty Pharma RPRX Stock Holding History

Marshall Wace North America’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$26.4M Buy
+731,667
New +$28.4M 0.11% 197
2020
Q4 		– Sell
-168,734
Closed -$7.1M – 1545
2020
Q3 		$7.1M Buy
168,734
+112,028
+198% +$4.81M 0.05% 333
2020
Q2 		$2.75M Buy
+56,706
New +$2.81M 0.02% 498

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace North America's RPRX Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Royalty Pharma (RPRX) in Q3 2021: 731,667 shares worth $26.4M. The stake represents 0.11% of the portfolio and ranks #197 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in RPRX as recently as Q3 2020.

Marshall Wace North America first reported a position in RPRX in Q2 2020 and has held it in 3 quarters since. 232 funds tracked by Wall St. Rank hold RPRX as of Q3 2021.

  • Marshall Wace North America held 731,667 shares of Royalty Pharma worth $26.4M as of Q3 2021.
  • Royalty Pharma was a new Marshall Wace North America position in Q3 2021.
  • Royalty Pharma made up 0.11% of Marshall Wace North America's portfolio in Q3 2021, its #197 holding.
  • Marshall Wace North America first reported a position in Royalty Pharma in Q2 2020 and has held it in 3 quarters since.
  • 232 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.